A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), and colorectal cancer (CRC))., cervical, cutaneous melanoma, esophageal, gastric, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), urothelial carcinoma

For Part 1, 2A, 2B: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs meeting protocol-defined Dose Limiting Toxicities (DLT) Criteria, AEs leading to discontinuation, death and laboratory abnormalities, For Part 2C: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by BICR

For Part 1, 2A, 2B: Maximum Observed Concentration (Cmax) of BMS-986288, For Part 1, 2A, 2B: Time of Maximum Observed Concentration (Tmax) of BMS-986288, For Part 1, 2A, 2B: Area Under the Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration AUC(0-T) of BMS-986288, For Part 1, 2A, 2B: Area Under the Concentration-Time Curve in one Dosing Interval AUC(TAU) of BMS-986288, For Part 1, 2A, 2B: Observed Concentration at the end of a Dosing Interval (Ctau) of BMS- 986288, For Part 1, 2A, 2B: Trough Observed Concentrations (Ctrough) of BMS-986288, For Part 1, 2A, 2B: Total Body Clearance (CLT) of BMS-986288, For Part 1, 2A, 2B: Average Concentration Over a Dosing Interval at Steady State (Cavgss) of BMS-986288, For Part 1, 2A, 2B: Accumulation Index (AI) of BMS-986288, For Part 1, 2A, 2B: Terminal Half-Life (T-HALF) of BMS-986288, For Part 1, 2A, 2B: Objective Response Rate (ORR) of Participants, For Part 1, 2A, 2B: Duration of Response (DOR) of Participants, For Part 1, 2A, 2B: Progression-Free Survival (PFS) of Participants, For Part 1, 2A, 2B: Time to Response (TTR) of Participants, For Part 2C: Objective Response Rate (ORR) by RECIST V1.1 by BICR, For Part 2C: Duration of Response (DOR) by RECIST V1.1 by BICR, For Part 2C: Progression-Free Survival (PFS) by RECIST V1.1 by BICR, For Part 2C: Overall Survival (OS) by RECIST V1.1 by BICR, For Part 2C: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs meeting protocol-defined Dose Limiting Toxicities (DLT) Criteria, AEs leading to discontinuation and death.

No related papers found yet.

France, Italy, Spain